beta

ALNA

Allena Pharmaceuticals Inc.

Alna

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

11-07-2018 08-07-2018 05-08-2018 03-27-2018 12-14-2017
Actual EPS -0.46 -0.42 -0.38 -0.48 -3.49
Consensus EPS -0.48 -0.41 -0.45 -0.27 -0.38
Estimated EPS -0.48 -0.41 -0.45 -0.27 -0.38
Number of Estimates 4 4 4 2 2
EPS Surprise $0.02 -$0.01 $0.07 -$0.21 -$3.11

Stats

Summary

Allena Pharmaceuticals Inc is a clinical biopharmaceutical company. It focuses on developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders.

Market Cap: 180 Million

Primary Exchange: Nasdaq Global Select

Website: http://www.allenapharma.com

Shares Outstanding: 20.7 Million

Float: 17.1 Million

Dividend: 0.0 (0.0%)

Beta: 2.713619

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 109 Thousand

Ethical Flags

Animal testing

Longest drawdown: 177 trading days

From: 2018-04-04 To: 2018-12-14

Lowest Point:

Allena Pharma's mid-stage basket study of ALLN-177 in hyperoxaluria underway

via: SeekingAlpha at 2018-07-23 09:20:26:000

The first subjects have been treated in an open-label Phase 2 basket study (Study 206) evaluating Allena Pharmaceuticals' (NASDAQ: ALNA ) lead candidate ALLN-177 in adults and adolescents with primary hyperoxaluria or enteric hyperoxaluria with advanced kidney disease and elevated plasma… read more...

Allena Pharma's mid-stage basket study of ALLN-177 in hyperoxaluria underway

via: SeekingAlpha at 2018-07-23 09:20:26:000

The first subjects have been treated in an open-label Phase 2 basket study (Study 206) evaluating Allena Pharmaceuticals' (NASDAQ: ALNA ) lead candidate ALLN-177 in adults and adolescents with primary hyperoxaluria or enteric hyperoxaluria with advanced kidney disease and elevated plasma… read more...

Allena Pharma's mid-stage basket study of ALLN-177 in hyperoxaluria underway

via: SeekingAlpha at 2018-07-23 09:20:26:000

The first subjects have been treated in an open-label Phase 2 basket study (Study 206) evaluating Allena Pharmaceuticals' (NASDAQ: ALNA ) lead candidate ALLN-177 in adults and adolescents with primary hyperoxaluria or enteric hyperoxaluria with advanced kidney disease and elevated plasma… read more...

Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges

via: SeekingAlpha at 2018-06-21 08:00:00:000

Analysis Focus: ANIK Anika Therapeutics ( ANIK ) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combin… read more...

Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges

via: SeekingAlpha at 2018-06-21 08:00:00:000

Analysis Focus: ANIK Anika Therapeutics ( ANIK ) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combin… read more...

Allena Pharma to file IND for ALLN-346 in H1 2019

via: SeekingAlpha at 2018-06-19 10:02:18:000

Allena Pharmaceuticals ( ALNA -0.6% ) has completed an animal proof-of-concept study supporting the rationale for ALLN-346 for the treatment of hyperuricemia (excess uric acid in the blood) in gout patients with associated chronic kidney disease (CKD). More news on: Allena Pharmaceutic… read more...

Allena Pharma to file IND for ALLN-346 in H1 2019

via: SeekingAlpha at 2018-06-19 10:02:18:000

Allena Pharmaceuticals ( ALNA -0.6% ) has completed an animal proof-of-concept study supporting the rationale for ALLN-346 for the treatment of hyperuricemia (excess uric acid in the blood) in gout patients with associated chronic kidney disease (CKD). More news on: Allena Pharmaceutic… read more...

Stocks To Watch: Apple, FOMC And China On Tap

via: SeekingAlpha at 2018-04-28 09:13:24:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. U.S. Treasury Secretary Steven Mnuchin is scheduled to lead a delegation to China f… read more...

Stocks To Watch: Apple, FOMC And China On Tap

via: SeekingAlpha at 2018-04-28 09:13:24:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. U.S. Treasury Secretary Steven Mnuchin is scheduled to lead a delegation to China f… read more...

Midday Gainers / Losers (04/06/2018)

via: SeekingAlpha at 2018-04-06 12:36:13:000

Gainers: NVCN +56% . LFIN +47% . OGEN +29% . BWEN +25% . CASI +16% . FORD +14% . MBII +10% . ABIL +10% . GEN +10% . TNTR +9% . More news on: Neovasc Inc., LongFin Corp, Oragenics, Inc., Stocks on the move, , Read more … read more...

Midday Gainers / Losers (04/06/2018)

via: SeekingAlpha at 2018-04-06 12:36:13:000

Gainers: NVCN +56% . LFIN +47% . OGEN +29% . BWEN +25% . CASI +16% . FORD +14% . MBII +10% . ABIL +10% . GEN +10% . TNTR +9% . More news on: Neovasc Inc., LongFin Corp, Oragenics, Inc., Stocks on the move, , Read more … read more...

Midday Gainers / Losers (4/3/2018)

via: SeekingAlpha at 2018-04-03 12:45:08:000

Gainers: MYND +66% . BPTH +33% . EBIO +23% . INNT +22% . ALNA +19% . CASI +19% . SSC +18% . URGN +18% . CLLS +17% . REFR +13% . More news on: MYnd Analytics, Inc., Bio-Path Holdings, Inc., Eleven Biotherapeutics, Inc., Stocks on the move, , Read more ….. read more...

Midday Gainers / Losers (4/3/2018)

via: SeekingAlpha at 2018-04-03 12:45:08:000

Gainers: MYND +66% . BPTH +33% . EBIO +23% . INNT +22% . ALNA +19% . CASI +19% . SSC +18% . URGN +18% . CLLS +17% . REFR +13% . More news on: MYnd Analytics, Inc., Bio-Path Holdings, Inc., Eleven Biotherapeutics, Inc., Stocks on the move, , Read more ….. read more...

Midday Gainers / Losers (4/2/2018)

via: SeekingAlpha at 2018-04-02 12:45:31:000

Gainers: SLS +167% . SSC +23% . MNOV +21% . ALNA +18% . MARK +15% . BLFS +15% . MBII +14% . CASI +12% . TCON +12% . CHCI +12% . More news on: SELLAS Life Sciences Group, Inc., Seven Stars Cloud Group, Inc., MediciNova, Inc., Stocks on the move, , Read m… read more...

Midday Gainers / Losers (4/2/2018)

via: SeekingAlpha at 2018-04-02 12:45:31:000

Gainers: SLS +167% . SSC +23% . MNOV +21% . ALNA +18% . MARK +15% . BLFS +15% . MBII +14% . CASI +12% . TCON +12% . CHCI +12% . More news on: SELLAS Life Sciences Group, Inc., Seven Stars Cloud Group, Inc., MediciNova, Inc., Stocks on the move, , Read m… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-04-02 08:39:10:000

BioXcel Therapeutics (Pending: BTAI ) initiated with Overweight rating and $15 (46% upside) price target at Barclays. Initiated with Buy rating and $18 price target at UBS. Initiated with Outperform rating and $23 price target at BMO Capital Markets. Initiated with Buy rating and $21 price t… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-04-02 08:39:10:000

BioXcel Therapeutics (Pending: BTAI ) initiated with Overweight rating and $15 (46% upside) price target at Barclays. Initiated with Buy rating and $18 price target at UBS. Initiated with Outperform rating and $23 price target at BMO Capital Markets. Initiated with Buy rating and $21 price t… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: March 12, 2018

via: SeekingAlpha at 2018-03-13 03:58:46:000

There was a small pullback in the U.S. equity indexes today. VIX was up more than 7% as investor hedged their portfolios ahead of the inflation, CPI data which will be released tomorrow at 8.30 am. IBB data by YCharts Esperion ( ESPR ) was volatile today after the release of cardiovas… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: March 12, 2018

via: SeekingAlpha at 2018-03-13 03:58:46:000

There was a small pullback in the U.S. equity indexes today. VIX was up more than 7% as investor hedged their portfolios ahead of the inflation, CPI data which will be released tomorrow at 8.30 am. IBB data by YCharts Esperion ( ESPR ) was volatile today after the release of cardiovas… read more...

3 Things In Biotech, March 8: A Tale Of 3 New Trials

via: SeekingAlpha at 2018-03-09 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Sea… read more...

3 Things In Biotech, March 8: A Tale Of 3 New Trials

via: SeekingAlpha at 2018-03-09 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Sea… read more...

Your Daily Pharma Scoop: Aclaris Gets Approval, Egalet Surges, Alnylam Gains As FDA Lifts Clinical Hold

via: SeekingAlpha at 2017-12-17 16:15:23:000

Content Analysis of coverage: ACRS Stocks in the news: EGLT, TSRO Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar Daily Trade Idea: (for TPT Subscribers only) Subscriber Questions & Answers (for T… read more...

Your Daily Pharma Scoop: Aclaris Gets Approval, Egalet Surges, Alnylam Gains As FDA Lifts Clinical Hold

via: SeekingAlpha at 2017-12-17 16:15:23:000

Content Analysis of coverage: ACRS Stocks in the news: EGLT, TSRO Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar Daily Trade Idea: (for TPT Subscribers only) Subscriber Questions & Answers (for T… read more...

Allena Pharmaceuticals reports Q3 results

via: SeekingAlpha at 2017-12-14 07:02:56:000

Allena Pharmaceuticals (NASDAQ: ALNA ): Q3 EPS of -$3.49 More news on: Allena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Allena Pharmaceuticals reports Q3 results

via: SeekingAlpha at 2017-12-14 07:02:56:000

Allena Pharmaceuticals (NASDAQ: ALNA ): Q3 EPS of -$3.49 More news on: Allena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2017-11-27 08:54:15:000

Allergan (NYSE: AGN ) resumed with Outperform rating and $237 (37% upside) price target by Leerink. More news on: Allergan plc, Allena Pharmaceuticals, CareDx, Healthcare stocks news, Stocks on the move, Read more … read more...

Stocks to watch next week

via: SeekingAlpha at 2017-11-25 08:18:50:000

Key events are scheduled for the companies listed below next week. More news on: Thoratec Corporation, Tech Data Corporation, Ferroglobe PLC, Consumer stocks news, Financial stocks news, Healthcare stocks news, Tech stocks news, Read more … read more...

Allena Pharmaceuticals: Complicated Phase III Filing

via: SeekingAlpha at 2017-11-16 14:43:18:000

Investment Thesis: Allena Pharmaceuticals ( ALNA ) is among the newest IPO's in the biotech space for 2017 having started trading on Nov 2nd following its IPO on Nov 1st. This company has two lead products in clinical and pre-clinical trials: ALLN-177 and ALLN 346 across multiple designation… read more...

U.S. IPO Weekly Recap: No Pop! For Funko In 9 IPO Week

via: SeekingAlpha at 2017-11-04 08:57:51:000

Average first-day pops ranged from -41% to +41% as nine deals raised a combined $2.1 billion this week. High-end software provider Altair was the top performer, returning 41% on its market debut, as investors valued its sticky customer base and track record of profitability. On the other end… read more...

Funko Plummets 41% In Biggest IPO Drop Since 2000

via: SeekingAlpha at 2017-11-03 03:14:25:000

Pop culture figurine maker Funko (FNKO) fell 41% on Thursday to close at $7.07 in the worst first-day return for an IPO in 17 years. The company priced a downsized IPO at $12 per share, below its range of $14-$16, to raise $125 million at a market cap of $580 million. Investors were likely c… read more...

Allena Pharmaceuticals prices IPO at low end of range

via: SeekingAlpha at 2017-11-01 19:58:44:000

Allena Pharmaceuticals (Pending: ALNA ) has priced its initial public offering at $14, according to IPO Boutique. More news on: Allena Pharmaceuticals, IPOs, Healthcare stocks news, Read more … read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX